Improving the management of patients after myocardial infarction, from admission to discharge

Clinical Therapeutics

Volumn 28, Issue 10, 2006, Pages 1509-1539

  Amin, Alpesh ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

cardiology; HF; hospitalist; LVD; post MI

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ATENOLOL; ATORVASTATIN; CAPTOPRIL; CARVEDILOL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; EPLERENONE; EPTIFIBATIDE; LISINOPRIL; LOSARTAN; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; PRAVASTATIN; PROPRANOLOL DERIVATIVE; RAMIPRIL; RETEPLASE; SIMVASTATIN; TENECTEPLASE; TICLOPIDINE; TIMOLOL; TIROFIBAN; TRANDOLAPRIL; UNINDEXED DRUG; VALSARTAN; ZOFENOPRIL;

ACUTE DRUG ADMINISTRATION; ANTICOAGULANT THERAPY; CARDIAC PATIENT; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; EVIDENCE BASED PRACTICE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE REPERFUSION; HEART REHABILITATION; HIGH RISK PATIENT; HOSPITAL CARE; HOSPITAL DISCHARGE; HOSPITAL MANAGEMENT; HOSPITALIZATION; HUMAN; MEDICAL INFORMATION; MEDICAL STAFF; MEDLINE; META ANALYSIS; MONOTHERAPY; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; REPEATED DRUG DOSE; REVIEW; SMOKING CESSATION PROGRAM; SYSTEMATIC REVIEW; UNSTABLE ANGINA PECTORIS;

CONTINUITY OF PATIENT CARE; HUMANS; MYOCARDIAL INFARCTION; PATIENT ADMISSION; PATIENT DISCHARGE; QUALITY OF HEALTH CARE;

EID: 33845189122     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.10.022     Document Type: Review

References (109)

1. Heart Disease and Stroke Statistics-2006 Update. A Report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee (2006), American Heart Association, Dallas, Tex
2. Steg P.G., Dabbous O.H., Feldman L.J., et al., Global Registry of Acute Coronary Events Investigators. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: Observations from the Global Registry of Acute Coronary Events (GRACE). Circulation 109 (2004) 494-499
3. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: Meta-analysis of individual data from 6500 patients in randomised trials. Lancet 350 (1997) 1417-1424
4. Velazquez E.J., Francis G.S., Armstrong P.W., et al., VALIANT Registry. An international perspective on heart failure and left ventricular systolic dysfunction complicat ing myocardial infarction: The VALIANT Registry. Eur Heart J 25 (2004) 1911-1919
5. Wu A.H., Parsons L., Every N.R., Bates E.R., and Second National Registry of Myocardial Infarction. Hospital outcomes in patients presenting with congestive heart failure complicating acute myocardial infarction: A report from the Second National Registry of Myocardial Infarction (NRMI-2). J Am Coll Cardiol 40 (2002) 1389-1394
6. Hasdai D., Topol E.J., Kilaru R., et al. Frequency, patient characteristics, and outcomes of mild-to-moderate heart failure complicating ST segment elevation acute myocardial infarction: Lessons from 4 international fibrinolytic therapy trials. Am Heart J 145 (2003) 73-79
7. Lanza G.A., Guido V., Galeazzi M.M., et al. Prognostic role of heart rate variability in patients with a recent acute myocardial infarction. Am J Cardiol 82 (1998) 1323-1328
8. [published correction appears in Circulation. 2005;111:2013-2014]. Antman E.M., Anbe D.T., Armstrong P.W., et al., American College of Cardiology, the American Heart Association Task Force on Practice Guidelines, and the Canadian Cardiovascular Society. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 110 (2004) e82-e292
9. 2003-2004 Survey by the Society of Hospital Medicine (SHM) on Productivity and Compensation: Analysis of Results, May 2004 (October 10, 2006). http://www.hospitalmedicine.org/AM/Template.cfm?Section=Search_Advanced_ Search§ion=Surveys&template=/CM/ContentDisplay.cfm&ContentFileID =248 6
10. Anderson S. The hospitalist. Radiol Manage 22 (2000) 57-60
11. Kober L., Torp-Pedersen C., Carlsen J.E., et al., Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensinconverting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 333 (1995) 1670-1676
12. Cleland J.G., Torabi A., and Khan N.K. Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction. Heart 91 Suppl 2 (2005) ii7-ii13
13. Wang T.J., Levy D., Benjamin E.J., and Vasan R.S. The epidemiology of "asymptomatic" left ventricular systolic dysfunction: Implications for screening. Ann Intern Med 138 (2003) 907-916
14. Available at:. Hunt S.A., Abraham W.T., Chin M.H., et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Accessed (October 10, 2006). http://circ.ahajournals.org/cgi/content/full/112/12/el54
15. Gheorghiade M., and Bonow R.O. Chronic heart failure in the United States: A manifestation of coronary artery disease. Circulation 97 (1998) 282-289
16. Fonarow G.C., Gawlinski A., Moughrabi S., and Tillisch J.H. Improved treatment of coronary heart disease by implemen tation of a Cardiac Hospitalization Atherosclerosis Management Program (CHAMP). Am J Cardiol 87 (2001) 819-822
17. Fonarow G.C., Stevenson L.W., Walden J.A., et al. Impact of a comprehensive heart failure management program on hospital readmission and functional status of patients with advanced heart failure. J Am Coll Cardiol 30 (1997) 725-732
18. Whellan D.J., Gaulden L., Gattis W.A., et al. The benefit of implementing a heart failure disease management program. Arch Intern Med 161 (2001) 2223-2228
19. Fonarow G.C., and Ballantyne C.M. Inhospital initiation of lipid-lowering therapy for patients with coronary heart disease: The time is now. Circulation 103 (2001) 2768-2770
20. Becker R.C., Bums M., Gore J.M., et al., National Registry of Myocardial Infarction (NRMI-2) Participants. Early assessment and in-hospital management of patients with acute myocardial infarction at increased risk for adverse outcomes: A nationwide perspective of current clinical practice. Am Heart J 135 (1998) 786-796
21. Becker R.C., Burns M., Every N., et al. Early clinical outcomes and routine management of patients with non ST-segment elevation myocardial infarction: A nationwide perspective. Arch Intern Med 161 (2001) 601-607
22. Bradley E.H., Herrin J., Mattera J.A., et al. Quality improvement efforts and hospital performance: Rates of betablocker prescription after acute myocardial infarction. Med Care 43 (2005) 282-292
23. Roe M.T., Parsons L.S., Pollack Jr. C.V., et al., National Registry of Myocardial Infarction Investigators. Quality of care by classification of myocardial infarction: Treatment patterns for ST- segment elevation vs non-ST-segment elevation myocardial infarction. Arch Intern Med 165 (2005) 1630-1636
24. Fonarow G.C., and Gawlinski A. Rationale and design of the Cardiac Hospitalization Atherosclerosis Man agement Program at the University of California Los Angeles. Am J Cardiol 85 (2000) 10A-17A
25. McCarthy M. US heart-guidelines strategy makes promising start. Lancet 358 (2001) 1618
26. Bart B.A., Ertl G., Held P., et al. Contemporary management of patients with left ventricular systol ic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur Heart J 20 (1999) 1182-1190
27. Fonarow G.C., Adams K., and Strausser B.P. ADHERE (Acute Decompensated Heart Failure National Registry): Rationale, design, and subject population. J Card Fail 8 (2002) 549
28. Cleland J.G., Cohen-Solal A., Aguilar J.C., et al., IMPROVEMENT of Heart Failure Programme Committees and Investigators. Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): An international survey. Lancet 360 (2002) 1631-1639
29. Wachter R.M. An introduction to the hospitalist model. Ann Intern Med 130 (1999) 338-342
30. Kulaga M.E., Charney P., O'Mahony S.P., et al. The positive impact of initiation of hospitalist clinician edu cators. J Gen Intern Med 19 (2004) 293-301
31. Hunter A.J., Desai S.S., Harrison R.A., and Chan B.K. Medical student evaluation of the quality of hospitalist and nonhospitalist teaching faculty on inpatient medicine rotations. Acad Med 79 (2004) 78-82
32. Wachter R.M. Hospitalists in the United States-mission accomplished or work in progress?. N Engl J Med 350 (2004) 1935-1936
33. Lindenauer P.K., Chehabeddine R., Pekow P., et al. Quality of care for patients hospitalized with heart fail ure: Assessing the impact of hospitalists. Arch Intern Med 162 (2002) 1251-1256
34. Dall L., Simmons T., Peterson S., and Herndon B. Beta-blocker use in patients with acute myocardial infarction treated by hospitalists. Manag Care Interface 13 (2000) 61-63
35. Dall L., Simmons T., Peterson S., and Herndon B. Beta-blocker use in patients with acute myocardial infarction treated by hospitalists. Manag Care Interface 13 (2000) 69
36. Auerbach A.D., and Pantilat S.Z. End-of-life care in a voluntary hospitalist model: Effects on communication, processes of care, and patient symptoms. Am J Med 116 (2004) 669-675
37. Joint Commission on Accreditation of Healthcare Organizations. Specification Manual for National Implementation of Hospital CoreMeasures: Version2.0 (implementation to begin with July 2004 discharges) (2004), JCAHO, Oakbrook Terrace, III
38. Koelling T.M., Johnson M.L., Cody R.J., and Aaronson K.D. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation 111 (2005) 179-185
39. Cline C.M., Israelsson B.Y., Willenheimer R.B., et al. Cost effective management programme for heart failure reduces hospitalisation. Heart 80 (1998) 442-446
40. Krumholz H.M., Amatruda J., Smith G.L., et al. Randomized trial of an education and support intervention to prevent readmission of patients with heart failure. J Am Coll Cardiol 39 (2002) 83-89
41. Kaboli P.J., Barnett M.J., and Rosenthal G.E. Associations with reduced length of stay and costs on an academic hospitalist service. Am J Manag Care 10 (2004) 561-568
42. [published correction appears in BMJ. 1994;308:1540]. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet thera py-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308 (1994) 81-106
43. Hall D., Zeitler H., and Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 20 (1992) 1549-1555
44. Spaulding C., Charbonnier B., Cohen-Solal A., et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: Results of a doubleblind, randomized comparative trial. Circulation 98 (1998) 757-765
45. Baur H.T., Schipperheyn J.J., van der Laarse A., et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Br Heart J 73 (1995) 227-236
46. [published correction appears in Lancet. 2003;361:90]. Teo K.K., Yusuf S., Pfeffer M., et al., ACE Inhibitors Collaborative Group. Effects of long-term treat ment with angiotensin-convertingenzyme inhibitors in the presence or absence of aspirin: A systematic review. Lancet 360 (2002) 1037-1043
47. [published corrections appear in N Engl J Med. 2001;345:1506 and N Engl J Med. 2001;345:1716]. Yusuf S., Zhao F., Mehta S.R., et al., Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
48. Chen Z.M., Jiang L.X., Chen Y.P., et al., COMMIT (CIOpidogrel and Metoprolol in Mycocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: Randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
49. Sabatine M.S., Morrow D.A., Montalescot G., et al., Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in STelevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Circulation 112 (2005) 3846-3854
50. Collins R., Peto R., Baigent C., and Sleight P. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocar dial infarction. N Engl J Med 336 (1997) 847-860
51. The SCATI (Studio sulla Calciparina nell'Angina e nella Trombosi Ventricolare nell'Infarto) Group. Randomised controlled trial of subcutaneous calcium-heparin in acute myocardial infarction. Lancet 2 (1989) 182-186
52. Cannon C.P. Importance of TIMI 3 flow. Circulation 104 (2001) 624-626
53. Theroux P., Alexander Jr. J., Pharand C., et al. Glycoprotein IIb/IIIa receptor blockade improves outcomes in diabetic patients presenting with unstable angina/non-ST-elevation myocardial infarction: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) study. Circulation 102 (2000) 2466-2472
54. Boersma E., Akkerhuis K.M., Theroux P., et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: Early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 100 (1999) 2045-2048
55. Stone G.W., Cox D., Garcia E., et al. Normal flow (TI MI-3) before mechanical reperfusion therapy is an inde pendent determinant of survival in acute myocardial infarction: Analysis from the primary angioplasty in myocardial infarction trials. Circulation 104 (2001) 636-641
56. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT -3 randomised trial in acute myocardial infarction. Lancet 358 (2001) 605-613
57. Topol E.J., and GUSTO V Investigators. Reperfusion therapyforacute myocardial infarction with fibri nolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial. Lancet 357 (2001) 1905-1914
58. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 304 (1981) 801-807
59. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. JAMA 247 (1982) 1707-1714
60. Lopressor Intervention Trial Research Group. The Lopressor Intervention Trial: Multicentre study of metopro lol in survivors of acute myocardial infarction. Eur Heart J 8 (1987) 1056-1064
61. Available at:. Braunwald E., Antman E.M., Beasley J.W., et al. ACC/AHA 2002 Guideline Update for the Management of Patients with Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Accessed (October 10, 2006). http://www.acc.org/qualityandscience/clinical/guidelines/unstable/incorp orated/index.htm
62. [published correction appears in Circulation. 2005;111: 2013]. Antman E.M., Anbe D.T., Armstrong P.W., et al., American College of Cardiology/American Heart Associa tion Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction). Circulation 110 (2004) 588-636
63. Commitment to Respond to COMMIT/ CCS-2 Trial Results: Beta Blocker Use for Myocardial Infarction (MI) Within 24 Hours of Hospital Arrival. ACC/ AHA/AHRQ/CMS/JCAHO Practice Advisory (April 27, 2005)
64. Chen Z.M., Pan H.C., Chen Y.P., et al., COMMIT (CIOpidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: Randomised placebocontrolled trial. Lancet 366 (2005) 1622-1632
65. Fonarow G.C. Practical considerations of beta-blockade in the management of the post-myocardial infarction patient. Am Heart J 149 (2005) 984-993
66. Pfeffer M.A., Braunwald E., Moye L.A., et al., SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med 327 (1992) 669-677
67. The Acute Infarction Ramipril Efficacy (AIRS) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342 (1993) 821-828
68. Torp-Pedersen C., Kober L., and TRACE Study Group (Trandolapril Cardiac Evaluation). Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. Lancet 354 (1999) 9-12
69. Dickstein K., Kjekshus J., and OPTIMAAL Steering Committee of the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: The OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. Lancet 360 (2002) 752-760
70. [published correction appears in N Engl J Med. 2004; 350:203]. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al., Valsartan in Acute Myocardial Infarction Trial Investigators. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 349 (2003) 1893-1906
71. Ambrosioni E., Borghi C., Magnani B., and Survival of Myocardial I nfarction Long-Term Evaluation (SMILE) Study Investigators. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med 332 (1995) 80-85
72. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 345 (1995) 669-685
73. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per to Studio della Soprawivenza nell'infarto Miocardico. Lancet 343 (1994) 1115-1122
74. Dargie H.J. Effect of carvedilol on outcome after myocardial infarction in patients with left -ventricular dysfunction: The CAPRICORN randomised trial. Lancet 357 (2001) 1385-1390
75. Kopecky S.L. Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. Am J Cardiol 98 (2006) 1115-1119
76. McMurray J., Kober L., Robertson M., et al. Antiarrhythmic effect of carvedilol after acute myocardial in farction: Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45 (2005) 525-530
77. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. JAMA 250 (1983) 2814-2819
78. Hjalmarson A., Elmfeldt D., Herlitz J., et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 2 (1981) 823-827
79. Hjalmarson A., Herlitz J., Holmberg S., et al. The Goteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 67 (1983) 126-132
80. The MIAMI Trial Research Group. Metoprolol in acute myocardial infarction. Mortality. Am J Cardiol 56 (1985) 156-226
81. The First International Study of Infarct Survival Collaborative Group. Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 2 (1986) 57-66
82. Roberts R., Rogers W.I., Mueller H.S., et al. Immediate versus deferred beta-blockade following thrombo lytic therapy in patients with acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 83 (1991) 422-437
83. [published correction appears in N Engl J Med. 2003;348: 2271]. Pitt B., Remme W., Zannad F., et al., Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003) 1309-1321
84. Ross S.D., Allen I.E., Connelly J.E., et al. Clinical outcomes in statin treatment trials: A meta-analysis. Arch Intern Med 159 (1999) 1793-1802
85. Stenestrand U., Wallentin L., and Swedish Register of Cardiac Intensive Care (RIKS-HIA). Early statin treat ment following acute myocardial infarction and 1-year survival. JAMA 285 (2001) 430-436
86. Sacks F.M., Pfeffer M.A., Moye L.A., et al., Cholesterol and Recurrent Events Trial investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 335 (1996) 1001-1009
87. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebocontrolled trial. Lancet 360 (2002) 7-22
88. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al., Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 285 (2001) 1711-1718
89. [published correction appears in N Engl J Med. 2006;354:778]. Cannon C.P., Braunwald E., McCabe C.H., et al., Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 (2004) 1495-1504
90. de Lemos J.A., Blazing M.A., Wiviott S.D., et al., A to Z Investigators. Early intensive vs a delayed conserva tive simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 292 (2004) 1307-1316
91. Mukherjee D., Fang J., Chetcuti S., et al. Impact of combination evidencebased medical therapy on mortality in patients with acute coronary syndromes. Circulation 109 (2004) 745-749
92. Mukherjee D., Fang J., Kline-Rogers E., et al. Impact of combination evidence based medical treatment in patients with acute coronary syndromes in various TI MI risk groups. Heart 91 (2005) 381-382
93. Boersma E., Pieper K.S., Steyerberg E.W., et al., PURSUIT Investigators. Predictors of outcome in patients with acute coronary syndromes without persistent ST segment elevation. Results from an international trial of 9461 patients. Circulation 101 (2000) 2557-2567
94. Califf R.M., Pieper K.S., Lee K.L., et al. Predictionof 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation 101 (2000) 2231-2238
95. Jacobs Jr. D.R., Kroenke C., Crow R., et al. PREDICT: A simple risk score for clinical severity and long-term prognosis after hospitalization for acute myocardial infarction or unstable angina: The Minnesota heart survey. Circulation 100 (1999) 599-607
96. Krumholz H.M., Chen J., Chen Y.T., et al. Predicting one-year mortality among elderly survivors of hospital ization for an acute myocardial infarction: Results from the Cooperative Cardiovascular Project. J Am Coll Cardiol 38 (2001) 453-459
97. Morrow D.A., Antman E.M., Charlesworth A., et al. TIMI risk score for ST elevation myocardial infarction: A convenient, bedside, clinical score for risk assessment at presentation: An intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation 102 (2000) 2031-2037
98. Morrow D.A., Antman E.M., Giugliano R.P., et al. A simple risk index for rapid initial triage of patients with ST-elevation myocardial infarction: An InTIME II substudy. Lancet 358 (2001) 1571-1575
99. Antman E.M., Cohen M., Bernink P.J., et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 284 (2000) 835-842
100. Fonarow G.C., Abraham W.T., Cannon C.P., et al., Post-Myocardial Infarction Guideline Committee. Role of beta-blocker therapy in the post-myocardial infarction patient with and without left ventricular dysfunction. Rev Cardiovasc Med 4 Suppl 3 (2003) S54-S59
101. Becker R.C. Complicated myocardial infarction. In: Cannon C.P., and O'Gara P.T. (Eds). Critical Pathways in Cardiology (2001), Lippincott Williams & Wilkins, Philadelphia, Pa 107-130
102. Eagle K.A., Montoye C.K., Riba A.L., et al., American College of Cardiology's Guidelines Applied in Practice (GAP) Projects in Michigan and the American College of Cardiology Foundation (Bethesda, Maryland) Guidelines Applied in Practice Steering Committee. Guideline-based standardized care is associated with substantially lower mortality in Medicare patients with acute myocardial infarction: The American College of Cardiology's Guidelines Applied in Practice (GAP) Projects in Michigan. J Am Coll Cardiol 46 (2005) 1242-1248
103. Eagle K.A., Kline-Rogers E., Goodman S.G., et al. Adherence to evidencebased therapies after discharge for acute coronary syndromes: An ongoing prospective, observational study. Am J Med 117 (2004) 73-81
104. Butler J., Arbogast P.G., BeLue R., et al. Outpatient adherence to betablocker therapy after acute myocardial infarction. J Am Coll Cardiol 40 (2002) 1589-1595
105. Ansari M., Shlipak M.G., Heidenreich P.A., et al. Improving guideline adherence: A randomized trial evaluating strategies to increase betablocker use in heartfailure. Circulation 107 (2003) 2799-2804
106. Hoekstra J.W., Pollack Jr. C.V., Roe M.T., et al. Im proving the care of patients with non-ST-elevation acute coronary syndromes in the emergency department: The CRUSADE initiative. Acad Emerg Med 9 (2002) 1146-1155
107. Cannon C.P., and Braunwald E. Strategies and therapies for reducing ischemic and vascular events (STRIVE) acute coronary syndromes critical pathway toolkit. Crit Pathways Cardiol 2 (2003) 153-177
108. Krumholz H.M., Anderson J.L., Brooks N.H., et al. ACC/AHA clinical performance measures for adults with ST-elevation and nonST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-STElevation Myocardial Infarction). Circulation 113 (2006) 732-761
109. Mehta R.H., Montoye C.K., Gallogly M., et al., GAP Steering Committee of the American College of Cardiology. Improving quality of care for acute myocardial infarction: The Guidelines Applied in Practice (GAP) Initiative. JAMA 287 (2002) 1269-1276